Physician profile
Jiwanjot Narula
NPI 1518158880
$1,859.41
in general payments reported to CMS, 2019-2025
17 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $127 · 2021: $206 · 2022: $18.72 · 2023: $279 · 2024: $514 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.00 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $321.73 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $199.45 | 2021-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $193.99 | 2020-2021 | |
| Travere Therapeutics, INC. | $180.81 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $148.39 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.76 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $118.10 | 2023-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $116.65 | 2023-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $105.40 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $79.85 | 2023-2025 | Rayaldee |
| Ardelyx, INC. | $66.24 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $51.61 | 2025 | |
| Amgen INC. | $48.95 | 2024-2025 | Tavneos |
| Nxstage Medical, INC. | $31.63 | 2020 | |
| Vifor Pharma, INC. | $31.47 | 2023 | Veltassa, Korsuva |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.48 | 2024 | Opticross 35 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.90 | 2024 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiwanjot Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.